Roche expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to develop broadly in line with sales growth, excluding the impact from the resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- VGK vs. EZU: Which Is the Better European Stock ETF?
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- FDA approves Genentech’s Alecensa for adjuvant treatment
- Roche announces data from its Phase III OCARINA II study of OCREVUS
